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Abstract
Cerebellar ataxia is a clinically heterogeneous group of disorders, which includes several well-characterized genetic
diseases as well as sporadic ataxias. The pathophysiology of ataxia is being understood, and a mechanistic basis for the
appearance of these disorders is progressively emerging. Novel genes associated with dominant and recessive ataxias are
being steadily identified, and research on their pathomechanisms not only has led to understanding the etiology and
underlying cause for the development of ataxia but also has steered the field towards future therapeutic regime, aiming to
control and prevent some forms of these diseases. Nevertheless, lack of knowledge for the causation of disease in a
sizeable proportion of patient remains, and this issue is further compounded by the rarity of some of these ataxias as well
as their restricted geographical distribution. On the other hand, large collaborative studies are providing critical infor-
mation on the clinical spectrum, progression, and pathophysiology of inherited and sporadic ataxias. In the following
sections, we describe the epidemiology, symptoms, pathological progression, and clinical management of various forms of
inherited cerebellar ataxias. Finally, we provide a perspective on the challenges faced by the field in translational research
and the development of successful therapeutic modalities for patients.
Keywords
Ataxia, spinocerebellar ataxia, episodic ataxia, genetics of cerebellar diseases, mechanisms of Purkinje cell degeneration,
therapies
Introduction
Ataxia refers to movements that are poorly coordinated,
originally derived from Greek, meaning lack of order. Dys-
function of the cerebellum and its input or output tracts can
lead to the development of ataxia.1,2 In some cases, there is
a combined involvement of cerebellar and extracerebellar
structures, particularly the brainstem. Loss of propriocep-
tive sensory feedback during movement and stance due to
the loss of function of muscle spindles leads to the devel-
opment of afferent ataxia, and symptoms are located to the
peripheral nerves localized to the, dorsal root ganglia
(DRG), and spinal cord.3 Current, global epidemiological
studies on ataxia have estimated an overall ataxia occur-
rence rate of 26/100,000 in children, and for dominant
hereditary cerebellar ataxia an occurrence rate of 2.7/
100,000, and the frequency of recessive hereditary cerebel-
lar ataxia as 3.3/100,000.4–7 The general rarity of ataxias as
a whole and the involvement of multitude of genetic factors
coupled with variable disease progression rates and diag-
nosis makes the field of ataxias highly challenging and
distinct from other neurodegenerative diseases.
Hereditary ataxias
Hereditary ataxia is a large and multifaceted group of dis-
eases affecting the cerebellum and its connections, all
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characterized by the development of ataxia as an early and
dominant feature of the disease. Nevertheless, the genetic,
pathophysiological, clinical, and neuropathological fea-
tures of these diseases are quite heterogeneous and varied.
Majority of the hereditary ataxias are transmitted as auto-
somal dominant or autosomal recessive traits, episodic
ataxias (EAs) have an autosomal dominant inheritance pat-
tern, and eight subtypes have been defined based on genetic
mutations and clinical characteristics. X-linked ataxias are
rare, with fragile X tremor ataxia syndrome (fragile X-asso-
ciated tremor/ataxia syndrome) being the most common in
this group of ataxias. Mitochondrial DNA (mtDNA) muta-
tions may lead to the development of ataxia together with
the presence of other debilitating neurological symptoms.
Point mutations in mtDNA are maternally transferred; sin-
gle deletions of mtDNA are often sporadic in nature, while
multiple mtDNA deletions and mtDNA depletion occur due
to inherited dominant or recessive nuclear DNA mutations.
Congenital ataxias are developmental disorders of the cer-
ebellum, inherited in an autosomal or X-linked recessive
manner.
Autosomal dominant cerebellar ataxia
Spinocerebellar ataxia (SCA) is a complex group of dom-
inantly inherited degenerative ataxias, numbered chronolo-
gically following their discovery order. Some exceptions to
the rule include SCA24, an autosomal recessive ataxia;
SCA29, a congenital nonprogressive ataxia; and SCA15/
16 and 19/22 which are allelic disorders. More than 49 SCA
forms attributed to at least 37 genes have been identified,
showing ethnic differences in their frequency and distribu-
tion,1 with an incidence of 3 per 100,000 in the European
population.8 The major clinical feature is impairment in
motor coordination and loss of movements, arising not only
due to the progressive loss of Purkinje cells in the cerebel-
lum but also due to degenerative changes in the brain stem
and spinocerebellar tracts, causing neurological symptoms
involving pyramidal and extrapyramidal manifestations.
The principal cause of the most common SCAs (SCA1,
2, 3, 6, 7, and 17) is a CAG trinucleotide repeat expansion
in specific genes, causing an expanded polyglutamine tract
(PolyQ) in the encoded proteins.9 These long PolyQ repeats
cause misfolding of proteins, which aggregate, forming
inclusions in the cytoplasm or nucleus of vulnerable neu-
rons, invariably contributing to the progression of the
pathology, neuronal dysfunctions, and subsequent neuronal
degeneration. The clinical prognosis depends on the length
of repeat expansion, and an inverse correlation exists
between the age of symptoms onset and the repeat length,
a phenomenon termed as anticipation. The anticipation
involves an increase in the length of expansion in subse-
quent generations, leading to an early development of
symptoms than the previous generation.10 The clinical
symptoms of PolyQ SCAs usually appear during adult-
hood, between the third and the fifth decades of life,11 with
consequent worsening and severe progression of the symp-
toms, culminating in death due to brainstem failure. The
first telltale symptom for a wide range of SCAs is the
appearance of abnormal gait, with additional manifesta-
tions depending on the mutated gene such as impaired
handwriting, dysarthria, intellectual disability, impaired
control of eye movement, and pyramidal and extrapyrami-
dal signs. An enigmatic question that remains to be deci-
phered is why certain neurons are exclusively affected,
since majority of the SCA-associated proteins are widely
expressed in different cell types, but predominantly Pur-
kinje cells are susceptible to neurodegeneration. In the fol-
lowing paragraphs, we describe the most common SCAs
and their characteristics in detail.
SCA1
SCA1 is caused by CAG expansion of more than 40 repeats
in the ATXN1 gene, encoding for Ataxin-1 protein, result-
ing in a toxic gain of function of Ataxin-1 protein leading to
tissue-specific neuronal loss. In humans and rodent model
of SCA1, Ataxin-1 is widely expressed throughout the
body, but Purkinje cells remain most vulnerable to the
mutated protein. The typical pathology observed in SCA1
patients involves primarily the olivopontocerebellar atro-
phy, loss of Purkinje cells, degeneration of different brain-
stem areas like basal pontine, and olivary nuclei and the
association of some of the cranial nerve nuclei involved in
motor control.8,12 In the spinal cord, degeneration of the
anterior horns, Clarke’s column, posterior columns, and
spinocerebellar tracts are observed.13,14 In some SCA1
cases, minor neuronal loss is present in the basal forebrain
cholinergic nuclei, cerebral cortex, and hippocampus.13,14
Ataxin-1 normally shuttles between the cytoplasm and
the nucleus of the cells, and the PolyQ expansion interferes
with this intra-organelle shuttling, leading to the retention
of the protein within the nucleus. Moreover, the presence of
specific domains within the Ataxin-1 protein such as AXH
domain has been implicated in RNA binding and self-
association and through this domain Ataxin-1 is able to
bind different proteins involved in RNA metabolism, bind-
ing, and transcription regulation.15–18 In murine models of
SCA1, impairment in protein interactions and dysfunctions
in RNA processing are key processes involved in SCA1-
associated degeneration.19 Majority of wild-type and
expanded Ataxin-1 assembles into large stable complexes
together with transcriptional repressor Capicua (CIC),
directly modulating CIC repressor activity in mammalian
cells, and a gain of function of this mechanism drives cer-
ebellar toxicity in SCA1.20,21 Early disease-related altera-
tions in critical intracellular pathways crucial for neuronal
functioning, that is, glutamate receptor signaling and
mechanistic target of rapamycin signaling, serving as
important integrators of biological metabolism and cellular
homeostasis have been implicated in the pathology of
SCA1.22,23 Mitochondrial dysfunctions and impairments
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in electron chain transport complexes have been observed
in preclinical models of SCA1, and ameliorating mitochon-
drial functioning deaccelerated the progression of the
pathology.24,25 Moreover, functional and morphological
alterations in the cerebellar circuitry involving both exci-
tatory and inhibitory inputs onto Purkinje cells,26–29 as well
as changes in intrinsic pacemaker firing of Purkinje cells,30
are observed, coinciding with specific disease stage.
SCA2
PolyQ expansion in the ATXN2 gene causes SCA2 pathol-
ogy. The age of onset for SCA2 can vary from infancy to
late adult life; infantile forms of SCA2 are mainly due to
hyper-expanded CAG repeats. SCA2 patients manifest
ataxia, slow saccadic eye movements, hyporeflexia, sen-
sory neuropathy, ocular palsies, and some degree of cogni-
tive impairment. Parkinsonism form of tremor is observed
due to the degeneration of dopaminergic neurons in the
substantia nigra.31 Similar to SCA1, most SCA2 patients
display olivopontocerebellar atrophy and comparable cere-
bellar cortical modifications; however, unlike SCA1 the
deep cerebellar nuclei remain largely spared in SCA2.32–34
Atrophy of the spinal anterior horn and degeneration of
spinocerebellar tracts and posterior columns are present.32,33
SCA2 CAG repeats whose length is at the limit between
normal and expanded alleles, though overall very rare, are
found significantly more often in patients with amyotrophic
lateral sclerosis (ALS),35 a risk factor for sporadic ALS36
and modifiers in chromosome 9 open reading frame 72
(C9ORF72) carriers, rendering susceptibility to ALS rather
than frontotemporal lobar degeneration. ATXN2 CAG
repeat, interrupted by trinucleotide CAA, is observed in
patients exhibiting prominent parkinsonism-associated fea-
tures and levodopa responsiveness.37–39
Several important studies have implicated Ataxin-2 pro-
tein in playing a crucial role in RNA metabolism, strength-
ened by evidences showing that Ataxin-2 interacting
proteins such as polyA-binding protein (PABP) and
RNA-binding protein called Ataxin-2 binding protein inter-
acted with Ataxin-2 via the PABP-interacting motif,
PAM2.40,41 Ataxin-2 is also involved in the assembly of
stress granules and P-bodies, major vesicular sites for the
regulation of both mRNA translation and degradation.42 As
intermediate CAG tract-repeat lengths in Ataxin-2 are a
risk factor for ALS, primarily in TDP-43 (43 kDa TAR
DNA-binding protein)-related ALS, similar to Ataxin-2,
TDP43 functions in regulating RNA metabolism, indicat-
ing that both the proteins might be involved in controlling a
common RNA metabolism pathway.43
SCA3
SCA3, also termed as Machado–Joseph disease, is caused
by an unstable CAG trinucleotide repeat in the ATXN3
gene. In comparison to SCA1 and SCA2, cerebellar cortex
and olivary nuclei are not majorly affected, and severe
degenerative pathology is present in the pontine nuclei and
deep cerebellar nuclei.44,45 Moreover, substantia nigra, glo-
bus pallidus, and subthalamic nuclei are also affected to a
certain extent but not observed in all patients.46 The clinical
symptoms are highly variable from very early onset
reported in young people to late onset, manifesting as dys-
arthria, oculomotor dysfunctions, rigidity, pyramidal signs,
and neuropsychological defects. This variable disease onset
and progression is classified into four different SCA3 sub-
types: type 1 is referred to as early onset and patients exhi-
bit stiffness and spasticity with nominal ataxia; type 2
appears in midlife with the development of progressively
increasing ataxia; type 3 has a late-in-life onset and symp-
toms also involve a neuropathic component; and type 4
occurs in patients who manifest the disease with a strong
parkinsonism component.13,47
Ataxin-3 is a relatively small protein (42 kD) shuttling
between the cytoplasm and the nucleus of the cells.
Wild-type Ataxin-3 appears particularly abundant in the
cytoplasm; however in the affected neurons it tends to
accumulate in the nucleus48 and is primarily involved in
quality control of proteins, working as a dedicated deubi-
quitinase (DUB). Currently, the precise pathogenesis of the
disease remains unclear, as in vivo study demonstrated that
mice lacking Ataxin-3 are normal except for the progres-
sive accumulation of polyubiquitin-positive proteins in the
brain. One plausible explanation for the pathogenesis of
SCA3 is that the conformational changes occurring in the
Ataxin-3 could alter the DUB function in multiple path-
ways involved in the ubiquitin protein control.8 Intrigu-
ingly and contrarily to expectations, the elimination of
Ataxin-3 from one of the transgenic mice line of yet
another common PolyQ expansion disease, that is, Hun-
tington’s disease (HD), did not accelerate the major symp-
toms of the HD pathology.49
SCA6
The affected gene in SCA6 encodes for 1A trans-
membrane subunit of the P/Q-type voltage-gated calcium
channel Cav2.1.50,51 In contrast to other SCAs, SCA6 is
considered a pure cerebellar disease because other brain
parts that are primarily affected in other SCAs seem to be
variably and negligibly affected in SCA6 patients.52 Cal-
cium homeostasis is a fundamental biological process in
neurons, tightly regulated via the expression of several cal-
cium channels. Interestingly, the Cav2.1 calcium channel is
particularly abundant in the primarily affected neurons in
SCAs of the Purkinje cells. To date, the possibility that the
mutation per se affects the functionality of the Cav2.1
channel, leading to the development of SCA6, is highly
debated. An alternative mechanism for toxicity involves
the generation of an expanded polyQ-containing C-
terminal domain via a process of cleavage of either 1A
subunit53 or generation of 1ACT a transcription factor
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through the translation of an internal ribosomal entry site in
Cav2.1 gene contributing to the pathology due to their
nuclear retention.54
Other PolyQ-linked SCAs
Three other PolyQ diseases, such as SCA7, SCA17, and
dentatorubral-pallidoluysian atrophy (DRPLA), are
caused due to CAG expansions in defined genes.55,56,57,58
In the case of SCA7, the expansion is observed in the
ATXN7 gene, and the pathophysiological and clinical
etiology is similar to those observed in SCA1, 2, and 3.
Unique to SCA7 is the presence of widespread retinal
degeneration.59 SCA17 is very rare, caused by a repeat
expansion in the TATA box-binding protein (TBP)
encoded by the TDP gene, which is involved in general
transcription.56 The PolyQ expansion might interfere with
TBP-mediated neuronal cell-specific transcription,
thereby causing neurodegeneration. DRPLA is also very
rare, and patients present strikingly heterogeneous clinical
symptoms.
Autosomal dominant spinocerebellar ataxia due to
non-coding repeat expansions
In a subset of SCAs such as SCA10, 12, 31, and 36, the
expansions occur within the non-coding region of the gene.
Non-coding ATTCT microsatellite repeat expansion in the
ATXN10 gene is causally linked to SCA10.60 This ATTCT
repeat is polymorphic, normally having a length of 9 to 32
ATTCT repeats in the overall population, but can expand
up to 4500 repeats in SCA10 patients.60,61 In few cases of
SCA10, the 50-end of the repeat expansion comprises a
complex sequence of penta- and hepta-nucleotide interrup-
tion motifs that are proceeded by a tract of tandem ATCCT
repeats of unknown length at its 30-end.62 Interestingly,
expansions carrying these specific penta- and hepta-
nucleotide interruption motifs show the presence of an epi-
leptic seizure phenotype. In SCA31, disease-causing
microsatellites comprising of pentanucleotide repeat com-
plexes, including (TGGAA)n, (TAGAA)n, (TAAAATA
GAA)n, and (TAAAA)n, within an intron shared by two
different genes, such as brain expressed associated with
NEDD41 (BEAN1) and thymidine kinase 2 (TK2), are
involved.63 RNA foci containing UGGAA repeats in Pur-
kinje cell nuclei of SCA31 patients, but absent in control
individuals, implicate (TGGAA)n as the crucial motif for
SCA31 pathogenesis, most likely via a gain-of-toxic-
function mechanism.64 Recent study has revealed a
mechanistic link between RNA and RNA chaperone-
TDP-43 in ribonucleoprotein complex homeostasis and
SCA31 pathology.65 In SCA36, a type of SCA accompa-
nied by motor neuron deficits, an intronic GGCCTG hex-
anucleotide repeat expansion in the NOP56 gene, is
implicated.66 Due to the presence of GGCCTG repeat, the
RNA transcribed from this gene causes nuclear aggregates,
wherein critical RNA binding proteins are trapped, forming
RNA foci, leading to the altered expression of crucial
genes.67 A similar repeat expansion mechanism for other
neurodegenerative diseases such as in C9ORF72-associ-
ated ALS is postulated.68
Other forms of autosomal dominant spinocerebellar
ataxia
The remaining SCAs do not show repeat expansion but
occur due to point mutations or deletions in the specific
genes. In most of the cases, the mutation is present within
genes, which encode for proteins important for normal
functioning of the cerebellum (see Table 1 for the descrip-
tion of genetic mutations and the symptoms of various
autosomal dominant spinocerebellar ataxias). An interest-
ing example is that of mutations in the gene encoding for
-III spectrin (SPTBN2), which lead to the development of
two human neurodegenerative diseases involving gait
ataxia and cerebellar atrophy. One of them is SCA type-5
(SCA5)69, and the other is spectrin-associated autosomal
recessive cerebellar ataxia type-1.70 In majority of SCAs
belonging to this group, implicated mutations are in genes
coding for proteins functioning in calcium homeostasis, ion
channels, mitochondria, cytoskeleton, and other intracellu-
lar pathways to which cerebellar Purkinje cells are
especially dependent on for their proper functioning. Het-
erozygous loss-of-function mutations clustering within the
proteolytic domain of AFG3L2, a mitochondrial resident
protein, cause SCA28 (Di Bella et al., 2010). AFG3L2
belongs to the AAA protease superfamily, assembling
together with paraplegin in the inner mitochondrial mem-
brane into homo-oligomers and hetero-oligomers, exerting
chaperone-like activity on respiratory chain complexes,
regulating the processing of the mitochondrial profusion
protein OPA1 and the subunit of mitochondrial ribosomes
MRPL32.71–73 Similarly, in SCA19/22 patients, mutations in
the voltage-gated potassium channel Kv4.3-encoding gene
KCND3 highlight the important role of ion channels as not
only main regulators of neuronal excitability but also in the
pathogenesis of cerebellar Purkinje cell degeneration.74
Autosomal recessive cerebellar ataxias
Autosomal recessive cerebellar ataxias (ARCAs) are char-
acterized by abnormal development and neurodegeneration
of the cerebellum and the spinal cord. Most ARCAs have
symptom onset during childhood or adolescent years, but
similar to SCAs variability is considerable and is inversely
dependent on the expansion size. As in the case of SCAs,
the first symptom to appear is gait imbalance, followed by
limb ataxia and dysarthria. The most frequent autosomal
recessive ataxia is Friedreich ataxia (FRDA), with a popu-
lation frequency of 1–2:50,000, caused by the mutation in
the FXN gene that encodes for the Frataxin protein leading
to loss of its function.75 In European populations, the
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occurrence of FRDA varies between 1:20,000 and
1:725,000 and accounts for >1/3 of ARCAs in Caucasians,
while all other ARCAs have a prevalence of one order of
magnitude less than FRDA, whereas in Japan, the most
common recessive ataxia is ataxia with oculomotor apraxia
type 1 (AOA1). Epidemiological studies have found the
existence of a west to east frequency gradient in Europe
with highest levels in the south of France, north of Spain
and Ireland and lowest levels in Scandinavia and Russia.76
The onset of symptoms usually appears before the age of 25
years, and patients affected by FRDA manifest dysarthria,
hyporeflexia, Babinski responses, sensory loss, and cardi-
omyopathy,77 with cardiac failure being the common cause
of mortality in FRDA. Major neurological symptoms
appear primarily due to the degeneration of DRG neurons,
large sensory neurons, and posterior columns. Wide spread
degeneration of spinocerebellar and corticospinal tracts of
the spinal cord is frequently observed and the dentate
nucleus of the cerebellum is affected, thereby causing a
cerebellar pathology.78,79
Frequently, the mutation consists in the expansion of a
GAA-triplet repeat in the first intron of the FXN gene, and
unlike dominant ataxia, this expansion is not associated
with the anticipation phenomena. Majority of FRDA indi-
viduals are homozygous for this mutation but in a few
cases, the patients carry a compound heterozygous GAA
Table 1. Mutations and symptoms linked to autosomal dominant spinocerebellar ataxias.a
SCA Gene Type of mutation Symptoms
SCA1 ATXN1 (CAG)n Pyramidal features, active reflexes, peripheral neuropathy,
and ophthalmoparesis
SCA2 ATXN2 (CAG)n Motor neuron involvement, peripheral neuropathy, slow
saccades, parkinsonian features, myoclonus, and dementia
SCA3 ATXN3 (CAG)n Pyramidal features, motor neuron involvement, peripheral
neuropathy, eyelid retraction, and parkinsonian features
SCA4 16q21.1 Unknown Peripheral neuropathy and pyramidal signs
SCA5 SPTBN2 Point mutations Tremor and facial myokymia
SCA6 CACNA1A (CAG)n Dysphagia, tremor, and somatosensory deficits
SCA7 ATXN7 (CAG)n Slow saccades, retinal macular degeneration, and dementia
SCA8 ATXN8 (CTG*CAG)n Pyramidal signs
SCA10 ATXN10 (ATTCT)n Dysphagia, seizures, and cognitive impairments
SCA11 TTBK2 Point mutations Pyramidal signs
SCA12 PPP2R2B (CAG)n Peripheral neuropathy, tremor, and parkinsonian features
SCA13 KCNC3 Point mutations Pyramidal signs and intellectual disability
SCA14 PRKCG Point mutations Dystonia and myoclonus
SCA15, 16 and 29 ITPR1 Point mutations, large deletions Tremor and dystonia
SCA17 TBP (CAG)n Parkinsonian features and dementia
SCA18 IFRD1 Point mutations Peripheral neuropathy
SCA19/22 KCND3 Point mutations, small deletions Myoclonus and dysphagia (SCA22)
SCA20 Unknown Genomic duplication Dysphonia and palatal tremor
SCA21 Unknown Unknown Parkinsonian features and mild cognitive impairment
SCA23 PDYN Point mutations Pyramidal features
SCA25 Unknown Unknown Peripheral neuropathy
SCA26 EEF2 Point mutations Dysarthria and eye movement abnormalities
SCA27 FGF14 Point mutations Tremor and dystonia
SCA28 AFG3L2 Point mutations Pyramidal features and ophthalmoparesis
SCA31 BEAN1 (TGGAA)n Dystonia
SCA35 TGM6 Point mutations Tremor and ocular dysmetria
SCA36 NOP56 (GGCCTG)n Motor neuron involvement
DRPLA ATN-1 (CAG)n Myoclonus, epilepsy, and dementia
SCA37 DAB1 ATTTC(n) Gait instability, dysarthria, and eye movement abnormalities
SCA38 ELOVL5 Point mutations Nystagmus and dysarthria
SCA40 CCDC88C Point mutations Ocular dysmetria and tremor
SCA41 TRPC3 Point mutations Imbalance and gait instability
SCA42 CACNA1G Point mutations Gait instability, dysarthria, and nystagmus
SCA43 MME Point mutations Peripheral neuropathy, dysarthria, and tremor
SCA44 GRM1 Point mutations Dysarthria, dysphagia, and dysmetria
SCA45 FAT2 Point mutations Dysarthria and nystagmus
SCA46 PLD3 Point mutations Eye movement abnormalities
SCA: spinocerebellar ataxia.
aViolet: SCAs with classical PolyQ expansions in the coding region of the gene; blue: SCAs with repeat expansions in the non-coding region of the gene;
black: SCAs arising due to point mutations or deletions; green: SCAs arising due to as of yet unidentified mutations
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expansion together with a different mutation (nonsense,
missense, deletions, and insertions).80–82 GAA expansion
causes transcriptional silencing of FXN, resulting in the
expression of a functionally normal Frataxin albeit at very
low levels, which are presumed to be estimated at approx-
imately 5–30% of normal levels (reviewed in83,84). The
encoded protein of FXN gene is located in the internal
membrane of the mitochondria; biological and physiologi-
cal roles of the Frataxin protein are not completely eluci-
dated, but, in recent years, studies have provided evidence
for a role of Frataxin in iron metabolism.85 In general,
Frataxin is a multifunctional protein involved in different
mitochondrial as well as other metabolic pathways. Recent
studies indicate that one prominent function of Frataxin is
in iron–sulfur cluster biogenesis, where it functions as an
allosteric activator of the cysteine desulfurase Nfs1.86,87
These small inorganic cofactors are involved in many cru-
cial cellular pathways extending from mitochondrial
respiration and metabolic processes to DNA synthesis and
repair.88 Autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS) is considered as the second most
common recessive ataxia with onset at childhood, present-
ing cerebellar ataxia, pyramidal spasticity, and peripheral
neuropathy.89 Originally identified in Quebec, cases are
currently documented worldwide. ARSACS results due to
loss of function mutation in SACS gene encoding for sac-
sin, a 4579-amino acid protein, localizing to the mitochon-
dria and participating in mitochondrial fission. Fibroblasts
from ARSACS patients show a hyper-fused mitochondrial
network, due to defects in mitochondrial fission as well as
Purkinje cell loss which have been documented from
patient brain.90,91 Besides, mitochondrial dysfunction com-
mon pathogenic mechanism in recessive ataxias involves
DNA repair defects (ataxia telangiectasia (A-T), AOA1,
and AOA2), impaired proteostasis and protein quality con-
trol (Marinesco-Sjogren syndrome), and vitamin E defi-
ciency (ataxia with vitamin E deficiency). Oxidative
stress might be involved and could play an essential role
mainly due to the connection with mitochondrial dysfunc-
tion as well as DNA damage.92 Intriguingly, a fraction of
recessive ataxias presents metabolic alterations as symp-
toms such as in Tay–Sachs disease, Sandhoff disease,
Niemann-Pick disease type C, leukodystrophies, cerebro-
tendinous xanthomatosis, and carbohydrate–glycoprotein
deficiency type 1a, seeming to be milder variants of meta-
bolic diseases, eventually making diagnosis difficult.93 In
yet another common recessive cerebellar ataxia, A-T, there
is an early and progressive onset of ataxia, oculomotor
apraxia, and immunodeficiency, and majority of cases
ataxia symptoms appear around 4 years of age.75 Telan-
giectasia is the second symptom to manifest, appearing
immediately after the development of cerebellar ataxia.
The early onset of the symptoms causes severe disability
and forces the patients to be wheelchair bound within few
years after symptoms onset. The mutation in the ATM gene
results in a mutated protein belonging to the
phosphoinositol-3 kinase-like serine/threonine kinases
family, playing a key role in critical checkpoint of the cell
cycle and of the DNA repair. A large number of patients
concomitantly develop leukemia and lymphoma with high
malignancy.94,95
Congenital ataxias
This group of ataxias mainly includes cerebellar structural
malformations, which compromises motor development,
and patients exhibit a form of stable nonprogressive ataxia.
Besides cerebellar and motor deficits, structural malforma-
tions affect also other regions of the CNS, and patients
exhibit hypotonia, apraxia, episodes of apnea, and cogni-
tive disabilities. Joubert syndrome and associated disorders
are the most common genetic congenital ataxias and belong
to a group of disorders termed as ciliopathies, which mainly
arises due to mutations in genes encoding for proteins of
the primary cilium, a microtubule containing extension of
the cell membrane essential for the development of many
tissues.96,97 Hence, it is not surprising that Joubert’s
patients often exhibit structural and functional malforma-
tions of other organs such as eyes, kidney, and liver.
X-linked degenerative ataxias
The major X-linked ataxia is FXTAS, a condition occurring
in carriers of intermediate length (premutation) alleles (50–
200 triplets) of the CGG repeat whose full expansion (9200
triplets) causes the fragile X syndrome of mental retarda-
tion. Higher prevalence of FXTAS is present in men around
50 years of age, characterized by the appearance of ataxia
and tremor. Notably, FXTAS also occurs in women, but
here the clinical manifestation of fragile X permutation is
premature ovarian failure rather than the development of
ataxia and tremor, indicating that the clinical scenario is
highly heterogeneous and complex.98
Episodic ataxias
EA belongs to a clinically diverse group of disorders, cate-
gorized by regular spells of undefined duration of trunk
ataxia and incoordination, which resolves after a certain
period.99,100 The prevalence of EA is less than 1/100,000
but might be underrated due to unidentified causative
genes. Most EAs have an autosomal dominant inheritance
pattern, although reports of the existence of few sporadic
cases are available.101 The underlying mutations are in
genes encoding for ion channels, and based on their clinical
features and genetic characterizations, eight subtypes are
recognized. The causative gene has been identified for four
of them: EA types 1, 2, 5, and 6.
EA type 1 (EA1) is associated with mutations in the
potassium channel gene KCNA1 and onset is during early
childhood. Patients exhibit brief episodes of ataxia with
constant interictal myokymia.99,100,102 The core features
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are imbalance, incoordination, and slurred speech, trig-
gered by physical and emotional stress or abrupt move-
ments. Usually, episodes of attacks last seconds to minutes.
EA type 2 (EA2) is associated with nonsense mutations
in the calcium channel gene, CACNA1A. The onset is
typically early in life and the episodes of recurrent ataxia,
such as slurred speech, can usually last for several hours,
and patients present various forms of interictal nystagmus
such as gaze-evoked nystagmus, rebound nystagmus, or
primary position downbeat nystagmus.103–105 Vertigo and
general weakness are commonly present and patients gra-
dually develop cerebellar symptoms.
Other EA subtypes
Other EA subtypes have been reported in small group of
families. EA3 was first described in a single large Canadian
family.106 EA4, also termed as periodic vestibulocerebellar
ataxia, was originally characterized in two kindreds, sug-
gesting a single common founder.107 EA5 is caused by a
mutation in the gene encoding for the calcium channel
CACNB4, identified in a French Canadian family.108
EA6 is attributed to a mutation in SLC1A3, identified in
two separate individuals.109,110 See Table 2 for a complete
list of mutations and symptoms related to EAs.
Treatment perspectives
Like with most neurodegenerative diseases, no cure or pre-
vention of the cerebellum-linked ataxias exists. Attempts to
develop a symptomatic treatment for ataxia have not yet
been very successful. Currently, emphasis of treatment for
cerebellar disorders mainly involves improving the quality
of life of patients. Lack of effective pharmacological options
that successfully cure the underlying cause of cerebellar
ataxia has led to focus on identifying symptoms associated
with or caused by ataxia and treating those symptoms. This
largely involves rehabilitation methods, which include
speech and swallowing therapy, physiotherapy aimed at
improving motor coordination, and occupational therapy.
Two large cohort studies have demonstrated the beneficial
effects of motor rehabilitation on individuals with
degenerative cerebellar diseases.111,112 A 12-h per week
regime involving physiotherapy with occupational therapy
in 42 patients suffering from degenerative cerebellar ataxias
led to remarkable improvements in ataxia severity, fall fre-
quency, and activities of daily living measured by the Func-
tional Independence Measure.113 Interestingly, patients
exhibiting predominant trunk ataxia presented much more
noticeable improvements as compared to patients having
limb ataxia. Moreover, patients with mild ataxia severity had
a longer sustained improvement in ataxic symptoms and gait
speed.112
Genetic targeting of PolyQ expansion in SCAs
and FRDA
For PolyQ expansion-related dominant SCAs, therapeutic
efforts largely involve inhibiting the expression of PolyQ
proteins via antisense oligonucleotides (ASOs) or artificial
microRNAs (miRNAs) or viral-mediated delivery of short
hairpin RNAs to interfere with the translation of PolyQ.
Most positive readouts for this type of approaches being
successful come from preclinical studies of ASOs or
miRNA-centered therapeutic interventions for SCA1,
SCA3,114 and SCA6.115 Remarkably, SCA2 ASOs were
not only able to reduce pathological hallmarks in SCA2
mice model,116 but they were also able to reduce the dis-
ease burden in the mouse model of TDP-43-associated
amyotrophic lateral sclerosis.117 In terms of prospective
delivery of ASOs, the experience and clinical trial success
of ASO-based therapy in children for another degenerative
disease, spinal muscular atrophy via lumbar puncture,118,119
and phase I clinical trial for ASOs in Superoxide dismutase 1
(SOD1)-mediated ALS120 provide proof that CNS delivery
of PolyQ-targeting ASOs is a feasible approach in the near
future. In preclinical rodent model of FRDA, hypertrophic
cardiomyopathy was reversed via intravenous injection of
adeno-associated virus rh10 vector expressing human
FXN, and administration of the frataxin-expressing viral
vector, after the onset of heart failure, was able to normal-
ize the cardiomyopathy of these mice at the functional,
cellular, and molecular levels.121
Table 2. Mutations and symptoms associated with episodic ataxias (EAs).
Episodic ataxia Gene Protein Symptoms
EA1 KCNA1 Potassium voltage-gated channel
a1 subunit (Kv1.1)
Vertigo, myokymia, epilepsy, dysarthria, weakness, tremor,
and incoordination
EA2 CACNA1A Calcium voltage-gated channel
a1 subunit (Cav2.1)
Nystagmus, vertigo, seizure, weakness, dysarthria, dystonia,
and cognitive impairment
EA3 Unknown Unknown Weakness, vertigo, visual blurring, and headache
EA4 Unknown Unknown Vertigo, diplopia, and nystagmus
EA5 CACNB4 Calcium voltage-gated channel
b4 subunit (Cav2.1)
Dysarthria, vertigo, nystagmus, and seizure
EA6 SLC1A3 Excitatory amino acid transporter 1 Weakness, seizure, vertigo, nystagmus, and dysarthria
EA7 Unknown Unknown Vertigo, weakness, and dysarthria
EA8 UBR4 E3 ubiquitin-protein ligase Vertigo, weakness, myokymia, and slurred speech
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Pharmacological compounds for the treatment of
cerebellar disorders
Aminopyridines (APs) are inhibitors of the potassium
channels, mainly blocking Kv1 family of voltage-
activated potassium channels. Antagonizing the activity
of these channels leads to increased excitability of neurons,
especially of cerebellar Purkinje cells as well as of other
cerebellar neurons.122 In preclinical mouse model of EEA2,
4-aminopyridine (4-AP) and closely related compound 3,4-
diaminopyridine improve the precision of pacemaker firing
of Purkinje cells,123 reducing the frequency of ataxia
attacks.124 Similarly, AP normalizes and improves the fir-
ing rate of Purkinje cells and motor behavior in ataxin-1
mutant mice.125 Importantly, in patients with A-T, 10 mg of
4-AP treatment restored the vestibule-cerebellum-mediated
inhibition on to the deep cerebellar nuclei, thereby reducing
the time constant of the angular vestibulo-ocular reflex and
improving the quality of life of patients.126
Besides cerebellar ataxias and gait disorders, 4-AP is
currently being recommended for the symptomatic control
of varied neurological dysfunctions such as in multiple
sclerosis, downbeat and upbeat nystagmus.127 Furthermore,
some EA2 and SCA6 patients show a beneficial response to
an anti-epileptic drug, acetazolamide.128 Randomized con-
trolled trial of riluzole on a mixed group of patients pre-
senting varied forms of dominant and recessive ataxia
exhibited an improvement in the severity of symptoms after
2 or 12 months of treatment.129,130 In yet another rando-
mized controlled trial of SCA3 patients, treatment with the
acetylcholine receptor agonist varenicline showed benefi-
cial effects on gait-related symptoms.131 Histone deacety-
lase inhibitor treatment regime of 30–240 mg/day was well
tolerated in FRDA patients and increased Frataxin mRNA
in peripheral blood mononuclear cells.132
Conclusion
The availability of newer drugs and treatment regime
largely depends on the speed at which research and new
rapid diagnostic technologies are developed. Current need
is to expand translational and back-translational research in
preclinical animal models, in parallel enhance the develop-
ment of novel animal models for rare cerebellar ataxias,
and to establish new imaging techniques, which would shed
continuous light on the pathology of cerebellar ataxias.
Since cerebellar ataxias by nature are quite diverse, impli-
cating genetic, clinical, and pathophysiological heteroge-
neity, the task of identifying novel therapies targeting
wide-ranging forms of ataxia remains challenging. More-
over, the uncommonness and the geographic restriction of
some forms of ataxia make large randomized controlled
trials difficult. Multicenter, multinational, and even intercon-
tinental efforts are needed to conclusively provide novel
therapies and cure from the underlying cause of ataxia.
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